{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T15:16:53Z","timestamp":1783091813615,"version":"3.54.6"},"reference-count":19,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2008,5,1]],"date-time":"2008-05-01T00:00:00Z","timestamp":1209600000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,9]],"date-time":"2019-12-09T00:00:00Z","timestamp":1575849600000},"content-version":"vor","delay-in-days":4239,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2008,5]]},"DOI":"10.1093\/annonc\/mdm600","type":"journal-article","created":{"date-parts":[[2008,2,13]],"date-time":"2008-02-13T21:54:55Z","timestamp":1202939695000},"page":"946-950","source":"Crossref","is-referenced-by-count":43,"title":["Phase II study of bortezomib in patients with previously treated advanced urothelial tract transitional cell carcinoma: CALGB 90207"],"prefix":"10.1016","volume":"19","author":[{"given":"J.E.","family":"Rosenberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Halabi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.L.","family":"Sanford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.L.","family":"Himelstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.N.","family":"Atkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.J.","family":"Hohl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Millard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.F.","family":"Bajorin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.J.","family":"Small","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mdm600_bb0010","doi-asserted-by":"crossref","first-page":"106","DOI":"10.3322\/canjclin.56.2.106","article-title":"Cancer statistics, 2006","volume":"56","author":"Jemal","year":"2006","journal-title":"CA Cancer J Clin"},{"key":"10.1093\/annonc\/mdm600_bb0015","doi-asserted-by":"crossref","first-page":"4602","DOI":"10.1200\/JCO.2005.07.757","article-title":"Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer","volume":"23","author":"von der Maase","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdm600_bb0020","doi-asserted-by":"crossref","first-page":"4776","DOI":"10.1200\/JCO.2005.05.081","article-title":"The ubiquitin-proteasome pathway and its role in cancer","volume":"23","author":"Mani","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdm600_bb0025","first-page":"841","article-title":"PS-341, a novel proteasome inhibitor, induces Bcl-2 phosphorylation and cleavage in association with G2-M phase arrest and apoptosis","volume":"1","author":"Ling","year":"2002","journal-title":"Mol Cancer Ther"},{"key":"10.1093\/annonc\/mdm600_bb0030","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.1038\/sj.leu.2403109","article-title":"The proteasome inhibitor bortezomib promotes mitochondrial injury and apoptosis induced by the small molecule Bcl-2 inhibitor HA14-1 in multiple myeloma cells","volume":"17","author":"Pei","year":"2003","journal-title":"Leukemia"},{"key":"10.1093\/annonc\/mdm600_bb0035","first-page":"6316","article-title":"The proteasome as a target for cancer therapy","volume":"9","author":"Voorhees","year":"2003","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdm600_bb0040","doi-asserted-by":"crossref","unstructured":"J Adams. Proteasome Inhibitors in Cancer Therapy. Totowa, NJ: Humana Press 2004","DOI":"10.1007\/978-1-59259-794-9"},{"key":"10.1093\/annonc\/mdm600_bb0045","first-page":"2505","article-title":"A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies","volume":"8","author":"Aghajanian","year":"2002","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdm600_bb0050","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(89)90015-9","article-title":"Optimal two-stage designs for phase II clinical trials","volume":"10","author":"Simon","year":"1989","journal-title":"Control Clin Trials"},{"key":"10.1093\/annonc\/mdm600_bb0055","doi-asserted-by":"crossref","first-page":"3173","DOI":"10.1200\/JCO.1999.17.10.3173","article-title":"Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy","volume":"17","author":"Bajorin","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdm600_bb0060","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2004.22.90140.546","article-title":"A phase II study of the proteasome inhibitor PS-341 in patients (pts) with metastatic breast cancer (MBC)","volume":"22","author":"Brown","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdm600_bb0065","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1093\/annonc\/mdj131","article-title":"Bortezomib (VELCADE(R)) in metastatic breast cancer: pharmacodynamics, biological effects, and prediction of clinical benefits","volume":"17","author":"Yang","year":"2006","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdm600_bb0070","doi-asserted-by":"crossref","first-page":"6111","DOI":"10.1158\/1078-0432.CCR-04-0422","article-title":"Phase II study of the proteasome inhibitor bortezomib (PS-341) in patients with metastatic neuroendocrine tumors","volume":"10","author":"Shah","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdm600_bb0075","doi-asserted-by":"crossref","first-page":"2584","DOI":"10.1002\/cncr.21108","article-title":"A phase II study of bortezomib in the treatment of metastatic malignant melanoma","volume":"103","author":"Svetomir","year":"2005","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdm600_bb0080","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1200\/JCO.2004.07.165","article-title":"Phase II trial of PS-341 in patients with renal cell cancer: a University of Chicago phase II consortium study","volume":"22","author":"Davis","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdm600_bb0085","doi-asserted-by":"crossref","first-page":"3720","DOI":"10.1200\/JCO.2004.10.155","article-title":"Phase II trial of bortezomib for patients with advanced renal cell carcinoma","volume":"22","author":"Kondagunta","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdm600_bb0090","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2005.23.16_suppl.7047","article-title":"The proteasome inhibitor PS-341 (bortezomib) in platinum (plat)-treated extensive-stage small cell lung cancer (E-SCLC): a SWOG (0327) phase II trial","volume":"23","author":"Johl","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdm600_bb0095","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s10637-006-9009-4","article-title":"A phase II study of PS-341 (bortezomib) in advanced or metastatic urothelial cancer: a trial of the Princess Margaret Hospital and University of Chicago phase II consortia","volume":"25","author":"Gomez-Abuin","year":"2007","journal-title":"Invest New Drugs"},{"key":"10.1093\/annonc\/mdm600_bb0100","doi-asserted-by":"crossref","first-page":"4420","DOI":"10.1200\/JCO.2002.01.133","article-title":"Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies","volume":"20","author":"Orlowski","year":"2002","journal-title":"J Clin Oncol"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092375341941853X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092375341941853X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/19\/5\/946\/23872132\/mdm600.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,20]],"date-time":"2020-02-20T08:34:52Z","timestamp":1582187692000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S092375341941853X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,5]]},"references-count":19,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2008,5]]}},"alternative-id":["S092375341941853X"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdm600","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2008,5]]}}}